CRNX News and Press, Crinetics Pharmaceuticals Inc. From 04/12/22

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) traded today at a new 52-week high of $41.00. So far today approximately 4.2 million shares have been exchanged, as compared to an average 30-day volume of 264,000 shares. Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is currently priced 2.4% a...

Shares of Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) traded at a new 52-week high today of $41.00. Approximately 4.2 million shares have changed hands today, as compared to an average 30-day volume of 268,000 shares. Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is currently priced 13.0...

Crinetics Pharmaceuticals (NASDAQ:CRNX) stock climbed 12% on positive data from the early trial of hyperinsulinism candidate CRN04777. JMP Securities raised CRNX price target to $45 from $43 and reiterated its Market Outperform rating. Analyst Jonathan Wolleben said Phase 1 data showed "clean...

Crinetics Pharmaceuticals press release (NASDAQ:CRNX):net loss $30.8M Revenue of $1.1M. For further details see: Crinetics Pharmaceuticals reports results

The clinical-stage biotech, Crinetics Pharmaceuticals (NASDAQ:CRNX), announced on Wednesday the topline results from the multiple-ascending dose (MAD) cohorts in its Phase 1 trial for the hyperinsulinism candidate, CRN04777. An oral nonpeptide somatostatin receptor type 5 (SST5) agonist, CRN0...

– Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Readouts in 2021 – – Advancing Phase 3 PATHFNDR Program Evaluating Paltusotine in Acromegaly – – Advancing a Pr...

Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call to Discuss Findings Today at 4:30 p.m. Eastern Time SAN DIEGO, March 30, ...

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a...

Clinical stage pharmaceutical company, Crinetics Pharmaceuticals (NASDAQ:CRNX), announced on Thursday that the preliminary results from its ongoing trial for CRN04894 are expected in the second quarter of 2022. CRN04894 is an investigational therapy designed to treat diseases of excess adreno...

SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a...